Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study.
作者信息
Musallam Khaled M, Cappellini Maria Domenica, Daar Shahina, Karimi Mehran, El-Beshlawy Amal, Graziadei Giovanna, Magestro Matthew, Wulff Jerome, Pietri Guilhem, Taher Ali T
机构信息
University of Milan, Ca Granda Foundation IRCCS, Ospedale Maggiore Policlinico, Milan, Italy American University of Beirut Medical Center, Lebanon.
University of Milan, Ca Granda Foundation IRCCS, Ospedale Maggiore Policlinico, Milan, Italy.
出版信息
Haematologica. 2014 Nov;99(11):e218-21. doi: 10.3324/haematol.2013.097220. Epub 2014 Jul 4.
Abstract
摘要
相似文献
1
Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study.中间型β地中海贫血非输血依赖患者的血清铁蛋白水平与发病风险：ORIENT研究
Haematologica. 2014 Nov;99(11):e218-21. doi: 10.3324/haematol.2013.097220. Epub 2014 Jul 4.
2
Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.血清铁调素作为重型β地中海贫血严重铁过载的诊断标志物。
Indian J Pediatr. 2017 Oct;84(10):745-750. doi: 10.1007/s12098-017-2375-4. Epub 2017 Jun 10.
3
Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.β 重型地中海贫血症患者经医学治疗后的血清铁蛋白水平与内分泌异常。
Ann Hematol. 2012 Jul;91(7):1107-14. doi: 10.1007/s00277-012-1412-7. Epub 2012 Jan 28.
4
Iron overload in β-thalassemia intermedia: an emerging concern.β-中间型地中海贫血中的铁过载：一个新出现的问题。
Curr Opin Hematol. 2013 May;20(3):187-92. doi: 10.1097/MOH.0b013e32835f5a5c.
5
Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation.血清铁蛋白不是判断重型地中海贫血患者造血干细胞移植后铁过载的可靠指标。
Eur J Haematol. 2018 Dec;101(6):791-797. doi: 10.1111/ejh.13169. Epub 2018 Oct 25.
6
Evaluation of Erythroferrone, Hepcidin, and Iron Overload Status in Iraqi Transfusion-Dependent β-Thalassemia Major Patients.评估伊拉克依赖输血的β-地中海贫血重型患者的红细胞生成素、铁调素和铁过载状态。
Hemoglobin. 2020 Jul;44(4):272-277. doi: 10.1080/03630269.2020.1794888. Epub 2020 Jul 27.
7
Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.非转铁蛋白结合的不稳定血浆铁和镰状细胞病中的铁过载：镰状细胞病与β地中海贫血病患者的对比研究。
Eur J Haematol. 2010 Jan 1;84(1):72-8. doi: 10.1111/j.1600-0609.2009.01342.x.
8
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.去铁胺与去铁酮联合治疗重型β地中海贫血输血性铁过载患者。
Ann Hematol. 2006 May;85(5):315-9. doi: 10.1007/s00277-005-0075-z. Epub 2006 Feb 1.
9
Association of HFE Gene Mutations With Serum Ferritin Level and Heart and Liver Iron Overload in Patients With Transfusion-dependent Beta-Thalassemia.铁调素基因 HFE 突变与输血依赖型β-地中海贫血患者血清铁蛋白水平及心肝铁过载的相关性。
J Pediatr Hematol Oncol. 2021 Jan;43(1):e26-e28. doi: 10.1097/MPH.0000000000001944.
10
Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.地拉罗司（恩瑞格®）对中间型β地中海贫血患者铁过载的调节作用
Hemoglobin. 2015;39(5):327-9. doi: 10.3109/03630269.2015.1057735. Epub 2015 Jun 26.
引用本文的文献
1
The Relationship Between Non-Transferrin-Bound Iron (NTBI), Labile Plasma Iron (LPI), and Iron Toxicity.非转铁蛋白结合铁（NTBI）、不稳定血浆铁（LPI）与铁毒性之间的关系
Int J Mol Sci. 2025 Jul 3;26(13):6433. doi: 10.3390/ijms26136433.
2
Non-Transfusion-Dependent Thalassemia: An Image Gallery Worth a Thousand Words.非输血依赖型地中海贫血：一幅胜过千言万语的影像图集。
Am J Hematol. 2025 Apr;100(4):687-694. doi: 10.1002/ajh.27621. Epub 2025 Jan 30.
3
Serum Iron and Ferritin Levels in Beta Thalassemia Carriers in Duhok Governorate, Iraq.伊拉克杜胡克省β地中海贫血携带者的血清铁和铁蛋白水平
Cureus. 2024 Jun 5;16(6):e61748. doi: 10.7759/cureus.61748. eCollection 2024 Jun.
4
Multiparametric cardiac magnetic resonance in patients with thalassemia intermedia: new insights from the E-MIOT network.中间型地中海贫血患者的心脏磁共振多参数成像：E-MIOT 网络的新见解。
Radiol Med. 2024 Jun;129(6):879-889. doi: 10.1007/s11547-024-01821-y. Epub 2024 Apr 29.
5
How I treat non-transfusion-dependent β-thalassemia.我如何治疗非输血依赖型β-地中海贫血。
Blood. 2023 Sep 14;142(11):949-960. doi: 10.1182/blood.2023020683.
6
Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.在非输血依赖型β-地中海贫血（NTDT）成人贫血治疗中 luspatercept 的概况：设计、开发和治疗中的潜在地位。
Drug Des Devel Ther. 2023 May 25;17:1583-1591. doi: 10.2147/DDDT.S368584. eCollection 2023.
7
Thalassemia Intermedia: Chelator or Not?中间型地中海贫血：螯合剂治疗，还是不治疗？
Int J Mol Sci. 2022 Sep 5;23(17):10189. doi: 10.3390/ijms231710189.
8
Iron overload status in patients with non-transfusion-dependent thalassemia in China.中国非输血依赖型地中海贫血患者的铁过载状况
Ther Adv Hematol. 2022 Mar 18;13:20406207221084639. doi: 10.1177/20406207221084639. eCollection 2022.
9
Impact of HFE-2 and HAMP Gene Variations on Iron Overload in Pediatric Patients with Non-Transfusion Dependent Thalassemia: A Pilot Study.HFE-2和HAMP基因变异对非输血依赖型地中海贫血患儿铁过载的影响：一项初步研究
Indian J Hematol Blood Transfus. 2022 Jan;38(1):158-163. doi: 10.1007/s12288-021-01442-9. Epub 2021 May 7.
10
Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study.斯里兰卡血红蛋白 E 地中海贫血患者的生存和并发症：一项前瞻性、纵向队列研究。
Lancet Glob Health. 2022 Jan;10(1):e134-e141. doi: 10.1016/S2214-109X(21)00446-0. Epub 2021 Nov 26.
本文引用的文献
1
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.地拉罗司有效地降低了非输血依赖型地中海贫血（NTDT）患者的铁过载：来自 THALASSA 研究的 1 年扩展结果。
Ann Hematol. 2013 Nov;92(11):1485-93. doi: 10.1007/s00277-013-1808-z. Epub 2013 Jun 18.
2
Non-transfusion-dependent thalassemias.非输血依赖型地中海贫血。
Haematologica. 2013 Jun;98(6):833-44. doi: 10.3324/haematol.2012.066845.
3
Treating iron overload in patients with non-transfusion-dependent thalassemia.治疗非输血依赖型地中海贫血患者的铁过载。
Am J Hematol. 2013 May;88(5):409-15. doi: 10.1002/ajh.23405. Epub 2013 Mar 8.
4
Iron overload in β-thalassemia intermedia: an emerging concern.β-中间型地中海贫血中的铁过载：一个新出现的问题。
Curr Opin Hematol. 2013 May;20(3):187-92. doi: 10.1097/MOH.0b013e32835f5a5c.
5
Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia.评估 5mg/g 肝铁浓度阈值及其与中间型β-地中海贫血患者发病的关系。
Blood Cells Mol Dis. 2013 Jun;51(1):35-8. doi: 10.1016/j.bcmd.2013.01.015. Epub 2013 Feb 18.
6
Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.非输血依赖型地中海贫血中的铁过载：临床视角。
Blood Rev. 2012 Apr;26 Suppl 1:S16-9. doi: 10.1016/S0268-960X(12)70006-1.
7
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.地拉罗司显著减少非输血依赖型地中海贫血的铁过载：一项前瞻性、随机、双盲、安慰剂对照研究的 1 年结果。
Blood. 2012 Aug 2;120(5):970-7. doi: 10.1182/blood-2012-02-412692. Epub 2012 May 15.
8
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia.肝铁浓度升高是中间型β地中海贫血患者发病率增加的标志物。
Haematologica. 2011 Nov;96(11):1605-12. doi: 10.3324/haematol.2011.047852. Epub 2011 Jul 26.
9
β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.β-地中海贫血：阐明无效红细胞生成和铁代谢动态调节的模型。
Blood. 2011 Oct 20;118(16):4321-30. doi: 10.1182/blood-2011-03-283614. Epub 2011 Jul 18.
Zotero 插件